ADVANCED COURSE Lisbon PORTUGAL. on Oncology/Hematology Therapy September. Centro Cultural de Belém - PDF

Description
LEARNING OBJECTIVES \ To understand the basic principles of Medical Oncology \ To understand how the main tumour types are approached in the clinic from diagnosis to therapy \ To get closed

Please download to get full document.

View again

of 8
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Information
Category:

Food

Publish on:

Views: 20 | Pages: 8

Extension: PDF | Download: 0

Share
Transcript
LEARNING OBJECTIVES \ To understand the basic principles of Medical Oncology \ To understand how the main tumour types are approached in the clinic from diagnosis to therapy \ To get closed to the practice of Oncology in a multidisciplinary setting \ To capture the importance of a molecular definition of tumours in the context of a modern precision Medicine CO-CHAIRS Mónica Nave Nazaré Rosado The volume of oncology drug information is expanding exponentially and the need for more emphasis on medication safety monitoring and assurance is imperative. There is an increasing need for specialized and well-trained oncology professionals and it is forecasted that the demand for highly motivated and properly credentialed professional teams in oncology will continue to increase for the foreseeable future! This HCPA Advanced Course aims to dotate professionals with the actual best practice and create opmportunities for knowledge sharing and collaboration!! FACULTY Mónica Nave \ Oncologist at Hospital da Luz, \ Member of the Portuguese Medical Society (Oncology) Nazaré Rosado \ Hospital Pharmacy Specialist - Ordem dos Farmacêuticos \ Lead pharmacist Aseptic Service at Hospital da Luz, Bruno Silva-Santos \ MD, PhD, Post-Doctoral \ Vice-Director of Instituto de Medicina Molecular \ Associate Professor at Faculdade de Medicina da Universidade de Lisboa Marta Soares \ MD, Medical Oncology \ Coordenadora da Unidade de Pulmão, \ Responsável da área médica da Unidade de Sarcomas, IPOPORTOFG John Valgus \ John Valgus, PharmD, BCOP, CPP \ Clinical Specialist, clinic based - Hematology/Oncology Clinic \ Clinical Assistant Professor - UNC Eshelman School of Pharmacy and UNC School of Medicine United States FACULTY Emanuel Gouveia \ MD, Medical Oncology \ IPOLFG, E.P.E. Fábio Lopes \ MD, Medical Oncology \ Hospital Beatriz Ângelo, Lisboa Azucena Aldaz \ Clinical Pharmacist \ Clinica Universidad de Navarra \ Grupo de Farmacia Oncológica de la SEFH Spain Cristina João \ MD \ Haematologist at Fundação Champalimaud, Lisboa \ Faculdade de Ciências Médicas, Universidade Nova de Lisboa Rui Bergantim \ MD \ Haematologist at Hospital São João, Porto \ PhD Student of the Cancer Drug Resistance Group at IPATIMUP SCIENTIFIC PROGRAM DAY 1-15 Sep THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH Monica Nave, MD Nazaré, PharmD A PRACTICAL REVIEW OF CANCER DIAGNOSIS, STAGING, PROGNOSIS AND THERAPY Monica Nave, MD SYSTEMIC ANTICANCER THERAPY: CLASSIC CHEMOTHERAPY AND TARGETED THERAPY Nazaré, PharmD CANCER IMMUNOTHERAPY Bruno Silva Santos, PhD THERAPY MANAGEMENT ON SOLID TUMORS NSCLC Marta Soares, MD, PT John Valgus, PharmD, US \ Diagnosis and staging \ Adjuvant and neoadjuvant setting \ New approaches oral therapies and immunotherapy \ Managing toxicities \ Clinical Cases Session DAY 2-16 Sep THERAPY MANAGEMENT ON SOLID TUMORS Melanoma Emanuel Gouveia, MD, PT John Valgus, PharmD, US \ Immunotherapy and Target therapy \ The best choice and best sequence \ Managing symptoms and toxicities \ Clinical Cases Session CANCER OF UNKNOWN PRIMARY: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE Fábio Lopes, MD, PT ARE PARP INHIBITORS READY FOR PRIME TIME? Mónica Nave, MD, PT DAY 3-17 Sep THERAPY MANAGEMENT ON HEMATOLOGIC MALIGNANCIES Myelodisplasic Syndromes Azucena Aldaz, PharmD, PhD, SP TBA ( to be announced), MD, US \ Classification, features, diagnosis and treatment options \ New molecules \ Supportive therapy IMMUNOTHERAPY IN HEMATOONCOLOGY Monoclonal Antibodies, Checkpoint Inhibitors and Cart Cells Cristina João, MD, PT Small Molecules (Anti-BTK and Anti-PI3K), Imunomodulation and Transplantation Rui Bergantim, MD, PT SCIENTIFIC COMMITTEE Mónica Nave, MD, Hospital da luz, PT Mª Nazaré Rosado, PharmD, Hospital da luz, PT Fernando FernandezLlimos, FFUL, PT ORGANISING COMMITTEE Andreia Duarte, HCPA Rui Rodrigues, HCPA REGISTRATION (Limited to 30 places) Registration values 2350 euros (VAT included) Venue (Sala Amália Rodrigues), Lisbon, Secretariat Social events Closure dinner on Friday, 16th EVENT OFFICIAL AGENCY Perfect Experiences RNAVT 3965 Rua da Junqueira 200 1º T F E flgx is a brand owned by Perfect Experiences. OUR MISSION IS PROMOTING EXCELLENCE IN MEDICINES MANAGEMENT The central objective of HCPA is to promote a complete training program aiming excellence, based on the current best practices of the various areas related to hospital medicines. Our trainings are delivered by recognized national and international health professionals with proven experience.
Related Search
Similar documents
View more...
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks